Shenzhen Weiguang Biological Products

SZSE:002880 Stock Report

Mkt Cap: CN¥5.7b

We’ve recently updated our valuation analysis.

Shenzhen Weiguang Biological Products Valuation

Is 2880 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2880?

Other financial metrics that can be useful for relative valuation.

2880 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.1x
Enterprise Value/EBITDA19.6x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 2880's PE Ratio compare to its peers?

2880 PE Ratio vs Peers
The above table shows the PE ratio for 2880 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average45.2x
688319 Chengdu Olymvax Biopharmaceuticals
57.4x41.3%CN¥5.5b
300149 Chempartner Pharmatech
8.8xn/aCN¥4.8b
688767 Hangzhou Biotest BiotechLtd
4.8xn/aCN¥4.9b
300683 Wuhan Hiteck Biological PharmaLtd
109.8xn/aCN¥4.3b
002880 Shenzhen Weiguang Biological Products
28.1xn/aCN¥5.7b

Price-To-Earnings vs Peers: 002880 is good value based on its Price-To-Earnings Ratio (28.1x) compared to the peer average (45.2x).


Price to Earnings Ratio vs Industry

How does 2880's PE Ratio compare vs other companies in the CN Biotechs Industry?

Price-To-Earnings vs Industry: 002880 is good value based on its Price-To-Earnings Ratio (28.1x) compared to the CN Biotechs industry average (29.6x)


Price to Earnings Ratio vs Fair Ratio

What is 2880's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2880 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 002880's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 2880 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002880 (CN¥25.22) is trading above our estimate of fair value (CN¥5.06)

Significantly Below Fair Value: 002880 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies